Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | See Remarks | August 19, 2026 | August 21, 2026 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | Chief Medical Officer | February 27, 2020 | March 02, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,592 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 1,697 · Balance 117,592 F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.
Verrica Pharmaceuticals Inc.
Report date February 27, 2020 · Filed March 02, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.81 · Expires 2030-02-26 | Direct | 55,000 |
Reported balance
After 2020-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-27 · Grant · Acquired 55,000 · Balance 55,000 F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2021 Filed Mar 5, 2021 20:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-005733 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon vesting. 25% of the RSUs vest annually on March 3 of each year, beginning March 3, 2022, subject to the Reporting Person's continued service to the Issuer. F2 · balance_after: Includes 9,500 RSUs. F3 · balance_after: Excludes 33,500 performance-based RSUs previously reported on Table I of Form 4 filed on 8/5/2020 which have not yet vested. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $25.89 | $0.00 |
DisclosureSEC source: 0001567619-20-014338 · doc1.xml · derivative · entry 2 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2030-08-03 F3 · derivative.exercise_date: The option vests as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| August 03, 2020 Filed Aug 5, 2020 21:02 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 33,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-014338 · doc1.xml · nonDerivative · entry 1 Burnett Patrick · CIK 0001741987 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 F1 · shares: Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 33,500 RSUs. The RSUs will begin vesting upon the achievement of the performance-based milestones. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:45 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001209191-20-014682 · doc4.xml · derivative · entry 1 Burnett Patrick · CIK 0001741987 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on February 27, 2021 and 1/48th of the total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:31 UTC | Verrica Pharmaceuticals Inc. VRCA · Entity 6823 | GrantEmployee Stock Option (Right to Buy) · Derivative | 52,508 | $0.00 Strike: $11.32 | $0.00 |
DisclosureSEC source: 0001209191-19-015818 · doc4.xml · derivative · entry 1 Burnett Patrick · CIK 0001741987 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,508 Underlying: Common Stock · 52,508 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of shares subject to the option shall vest on February 28, 2020 (the "Initial Vesting Date"), and 1/48th of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Initial Vesting Date, subject to the Reporting Person continuing to be a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.